ARTICLE | Company News

GSK expects Advair price crunch, ViiV IPO decision

February 5, 2015 2:24 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects continued price pressure on respiratory drug Advair salmeterol/fluticasone propionate this year and said it is likely to reveal a decision on a partial IPO of HIV joint venture ViiV Healthcare Ltd. (Brentford, U.K.) in its 2Q15 earnings update.

On the company's 4Q14 earnings call on Wednesday, CEO Andrew Witty said GSK has negotiated contracts with payers that add Advair to U.S. formularies, "albeit at lower price levels," and expects slower sales of the drug in 2015. ...